Latest Biotech News

AI protein design company Profluent closed a $106 million financing led by Altimeter Capital and Bezos Expeditions to expand large‑scale models for protein design and commercialize bespoke...

Function Health closed a $298 million Series B led by Redpoint Ventures, valuing the company at $2.5 billion. The Austin‑based lab testing and imaging subscription startup offers consumers access...

A bipartisan group of senators and representatives introduced legislation to establish a National Biopharmaceutical Manufacturing Center of Excellence (COE) to accelerate domestic biomanufacturing...

Companies warned that proposals under the Trump administration and statements by Health Secretary Robert F. Kennedy Jr. could force major changes to vaccine formulations and schedules. Reporting...

Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to add Halda’s precision oncology assets to its pipeline. The deal centers on HLD-0915, a clinical-stage prostate...

Merck agreed to acquire Cidara Therapeutics for $9.2 billion to secure CD388, a long-acting, strain-agnostic influenza antiviral in Phase III. CD388 combines a neuraminidase-targeting small...

Bloomberg reported Abbott Laboratories is in talks to acquire cancer-testing firm Exact Sciences, a move that sent Exact’s shares sharply higher. Exact manufactures the stool-based colorectal...

Roche and Freenome struck a multi-year collaboration giving Roche exclusive ex‑US commercialization and kit‑development rights for Freenome’s blood-based cancer screening tests, alongside a $75...

Arrowhead Pharmaceuticals secured FDA approval for its RNAi therapy plozasiran (Redemplo) for familial chylomicronemia syndrome, marking the company’s transition to a commercial-stage biopharma....

Tessera Therapeutics confirmed it will commence the first human trial of its in vivo gene writing platform next month, testing the approach in adults with a rare genetic disease (alpha‑related...

Oncolytics Biotech announced alignment with the FDA on the pivotal Phase III trial design of pelareorep combined with standard‑of‑care therapy for first‑line metastatic pancreatic ductal...

Profluent closed a $106 million financing round led by Altimeter Capital and Bezos Expeditions to scale large AI models for protein design across therapeutics, agriculture, and biomanufacturing....

Function Health raised $298 million in a Series B led by Redpoint Ventures, pushing its valuation to about $2.5 billion. The consumer lab‑testing company plans to expand its direct‑to‑consumer...

GSK entered a collaboration with LTZ Therapeutics to develop up to four myeloid cell engager candidates using LTZ’s immune‑engager platform, paying $50 million upfront. The partnership targets...

Arrowhead Pharmaceuticals secured U.S. regulatory approval for plozasiran (Redemplo) to treat familial chylomicronemia syndrome, and immediately positioned the drug at a markedly lower list price...

Johnson & Johnson agreed to acquire Halda Therapeutics for roughly $3.05 billion in cash to add Halda’s RIPTAC-based precision oncology portfolio, including a clinical-stage prostate cancer...

Roche reported positive Phase 3 data for its oral selective estrogen receptor degrader (SERD), giredestrant, showing a statistically significant improvement in invasive disease-free survival in...

Merck agreed to acquire Cidara Therapeutics for $9.2 billion to add CD388, a long-acting, strain-agnostic antiviral designed for influenza prevention in high-risk populations. CD388 combines a...

Merck reported that its once-daily two-drug islatravir combination was non-inferior to a three-drug regimen in a Phase 3 study, marking another clinical success in the company’s effort to expand...

Profluent closed a $106 million financing led by Altimeter Capital and Bezos Expeditions to expand its large‑scale AI models for protein design and commercialize across therapeutics, agriculture...